ArticleBreast (Edinburgh, Scotland)2026
Secondary dry eye disease in breast cancer patients: a pilot study.
Article in Breast (Edinburgh, Scotland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Excessive Tearing and Lacrimal and Canalicular Blockage Secondary to Docetaxel in Breast Cancer Patients in the Metastatic and Adjuvant Settings.Current oncology (Toronto, Ont.) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate ocular surface alterations associated with oncological therapy in patients with hormone receptor-positive (HR+) breast cancer.
methodsIn this prospective pilot study, 30 HR + breast cancer patients and 10 age-matched healthy controls were evaluated at three time points: before surgery (T0), one week after surgery before starting therapy (T1), and after 12 months of antiestrogenic treatment (T2). Clinical assessments included Ocular Surface Disease Index (OSDI), Visual Function Questionnaire-25 (VFQ-25), Schirmer test type I, tear break-up time (TBUT), Meibomian gland dysfunction (MGD) score, and corneal and conjunctival staining. Gene expression of IL-6 and ICAM-1 was analyzed via impression cytology.
resultsNo differences were observed between cancer patients and controls at baseline. After surgery (T1), patients reported increased OSDI scores (p < 0.05), reduced TBUT (p < 0.01), and worse MGD scores (p < 0.01). After 12 months of treatment (T2), MGD scores, Schirmer test values, and ocular staining worsened significantly (p < 0.01), along with a decline in VFQ-25 scores (p < 0.05). IL-6 and ICAM-1 expression were significantly upregulated at T2. Postmenopausal women experienced more severe ocular surface dysfunction than premenopausal patients.
conclusionsAntiestrogen therapy in HR + breast cancer patients induces progressive ocular surface dysfunction, driven by chronic inflammation and epithelial damage. These findings highlight the importance of recognizing ocular symptoms in this population and support further studies evaluating the role of routine ophthalmologic monitoring in survivorship care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.